Clinical research - Press Releases

Date	Title	Company
15-Dec-2021	Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH’s plenary and late-breaking sessions	Sanofi
15-Dec-2021	Egetis intends to submit a marketing authorisation application for Emcitate® to the European Medicines Agency based on existing clinical data	Egetis Therapeutics AB
15-Dec-2021	Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study	Idorsia
15-Dec-2021	EQT Private Equity and Goldman Sachs Asset Management Complete Acquisition of Parexel	Parexel
14-Dec-2021	HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting	HUTCHMED
10-Dec-2021	IDDI celebrates its 30th anniversary this year	IDDI
09-Dec-2021	New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma	New England Journal of Medicine
07-Dec-2021	Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th Annual 3D Cell Culture Conference	SMi Group
07-Dec-2021	Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV	Vaccitech plc
07-Dec-2021	SynDevRx Announces Research Collaboration with Queensland University of Technology (QUT) to Study the Effects of SDX-7320 In Advanced Prostate Cancer Models	SynDevRx
06-Dec-2021	Six Key Presentations at SMi's Inaugural Robotics & Automation in Pharma Conference	SMi Group
03-Dec-2021	Acumen Diagnostics' PCR capabilities to tackle Omicron COVID-19 variant	Acumen Diagnostics
02-Dec-2021	Emmes Announces Completion of Third ACTT Clinical Trial for COVID-19	Emmes
02-Dec-2021	CloudLIMS’ Complimentary Talk on the USDA's New Hemp Testing Rules	CloudLIMS
26-Nov-2021	7 Key Takeaways from SMi’s 10th Annual Pharmaceutical Microbiology Conference	SMi Group
22-Nov-2021	Amerigo Scientific Announces Offering of Human Plasmin, Recombinant	Amerigo Scientific
22-Nov-2021	CD Bioparticles Introduces Customizable MOFs Linkers for Research Use	CD Bioparticles
22-Nov-2021	Amerigo Scientific Launches Human Pro-Glu-Plasminogen, Recombinant for Research Use	Amerigo Scientific
22-Nov-2021	STEMart Introduces Medical Device Risk Assessments Services	STEMart
24-Oct-2021	SMi Group Launches new conference: The Transdermal and Microneedle Delivery Conference	SMi Group